Form 4: MapLight Therapeutics CFO Receives Stock Grant
Insider Transaction (Form 4)
Jonathan Gillis, CAO and Interim CFO of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.
Summary
- Grant/award: acquired 6,020 Voting Common Stock on August 17, 2026; holds 150,260 after (Direct).
- Grant/award: acquired 2,222 Voting Common Stock on August 17, 2026; holds 152,482 after (Direct).
- Grant/award: acquired 24,455 Employee Stock Option (right to buy) on August 17, 2026; holds 24,455 after (Direct).
- Grant/award: acquired 2,813 Employee Stock Option (Right to Buy) on August 17, 2026; holds 2,813 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jonathan Gillis — Officer (CAO and Interim CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Grant/award | Voting Common Stock | 6,020 | — | — | 150,260 |
| 2026-08-17 | Grant/award | Voting Common Stock | 2,222 | — | — | 152,482 |
| 2026-08-17 | Grant/award | Employee Stock Option (right to buy) | 24,455 | — | — | 24,455 |
| 2026-08-17 | Grant/award | Employee Stock Option (Right to Buy) | 2,813 | — | — | 2,813 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Grant/award (6,020 shares) |
| 2026-08-17 | Grant/award (2,222 shares) |
| 2026-08-17 | Grant/award (24,455 shares) |
| 2026-08-17 | Grant/award (2,813 shares) |
Keywords
insider transaction, Form 4, MPLT, MapLight Therapeutics, Inc., neutral, Jonathan Gillis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.